Table 4 Univariate analysis of overall survival in GBC patients

Gender

Male

37

14

1.23 (0.76, 2.01)

0.392

Female

78

11

Age

≤60 years

29

16

0.66 (0.38, 1.13)

0.122

>60 years

86

11

Associated gallstone

Absent

39

13

0.68 (0.43, 1.09)

0.105

Present

76

12

ALT

≤75 U/L

85

12

1.35 (0.75, 2.41)

0.315

>75 U/L

32

10

AST

≤38 U/L

78

13

1.24 (0.72, 2.13)

0.437

>38 U/L

37

11

Serum total bilirubin

≤12 mg/dL

60

14

1.50 (0.91, 2.45)

0.107

>12 mg/dL

55

10

Albumin

<35 g/dL

29

11

0.82 (0.45, 1.48)

0.506

≥35 g/dL

86

12

Hemoglobin

≤125 g/dL

53

10

0.54 (0.34, 0.88)

0.012

>125 g/dL

49

15

WBC count

≤6.8 × 10³/mm³

57

15

1.65 (1.03, 2.64)

0.035

>6.8 × 10³/mm³

45

9

Fibrinogen

≤402 mg/dL

60

17

0.48 (0.31, 0.75)

0.001

>402 mg/dL

55

8

Platelet count

≤215 × 10⁴/mm³

58

13

1.44 (0.92, 2.24)

0.108

>215 × 10⁴/mm³

57

11

CA19-9

≤35 U/mL

54

13

1.36 (0.82, 2.25)

0.239

>35 U/mL

61

10

CEA

≤10 ng/mL

62

13

1.61 (0.94, 2.76)

0.078

>10 ng/mL

53

11

CA125

≤35 U/mL

66

12

1.60 (0.89, 2.88)

0.11

>35 U/mL

49

11

Histologic differentiation

Well

15

32

0.51 (0.36, 0.72)

<0.001

Moderate

59

13

Poor and undifferentiated

41

8

Tumor invasion

Tis and T₁

20

32

4.58 (2.15, 9.76)

<0.001

T₂, T₃ and T₄

91

11

Lymph node metastasis

Absent

73

17

4.08 (2.49, 6.67)

<0.001

Present

42

7

TNM stage

0 and I

29

33

5.97 (2.78, 12.82)

<0.001

II and IV

86

11

Margin status

R0

69

20

0.14 (0.09, 0.24)

<0.001

R1

46

6

Combined hepatectomy

No

51

11

0.94 (0.59, 1.49)

0.792

Yes

54

12

Combined CBD resection

No

87

14

2.06 (1.15, 3.69)

0.013

Yes

18

9

Lymphadenectomy

No

15

8

1.89 (1.01, 3.56)

0.044

Yes

83

12